Early Access to Nulibry®
Nulibry® is approved by the US Food and Drug Administration (FDA) for patients with molybdenum cofactor deficiency (MoCD) Type A. Nulibry is only commercially available in the US at this time. Nulibry is available outside of the US via an Early Access Program for patients who meet specific criteria. An Early Access Program is a compliant mechanism through which a healthcare professional can request a medicine that is not commercially available in their country of residence for patients who have serious illnesses, have no alternative treatment options, and who cannot enroll in a clinical trial for treatment. The Nulibry Early Access Program is being managed by Inceptua. Inceptua can only consider requests for access to Nulibry from qualified healthcare professionals; requests for early access to Nulibry for patients outside of the US should be directed to Inceptua at: access@inceptua.com.
